| Identification | Back Directory | [Name]
Benzamide, N-[2-bromo-4-(phenylsulfonyl)-3-thienyl]-2-chloro- | [CAS]
685119-25-9 | [Synonyms]
BNTA
Benzamide, N-[2-bromo-4-(phenylsulfonyl)-3-thienyl]-2-chloro- | [Molecular Formula]
C17H11BrClNO3S2 | [MOL File]
685119-25-9.mol | [Molecular Weight]
456.76 |
| Hazard Information | Back Directory | [Uses]
BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation[1]. | [in vivo]
BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats[1]. | Animal Model: | Male SD rats weighing 80?g are induced by ACLT[1] | | Dosage: | 0.015, 0.15, 1.5 mg/kg | | Administration: | Intra-articular injection; twice a week for 4 and 8 weeks | | Result: | Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated. |
| [References]
[1] Shi Y, et, al. A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. Nat Commun. 2019 Apr 23; 10(1): 1914. DOI:10.1038/s41467-019-09839-x |
|
| Company Name: |
nanjing
|
| Tel: |
13376082704 |
| Website: |
www.linye-e.com/ |
|